June 22, 2025; Kampala – Uganda :DEI BioPharma, a leading pharmaceutical and biological drugs company in Uganda, announced today its plan to manufacture active pharmaceutical ingredients (APIs) in Uganda for products protected by global patents, which are currently unaffordable to most developing countries. Uganda, as a listed LDC in the patent-free country category under the TRIPS Agreement of the United Nations until 2034, is starting its project with a new drug for the treatment of HIV, Lenacapavir (Yeztugo), a novel HIV-1 capsid inhibitor developed by Gilead Sciences. This drug was approved by the FDA on June 18, 2025. However, its price of $28,000 per year is unaffordable to all developing countries where it is needed most. Now, DEI BioPharma will be able to supply the same product to all LDCs for less than $50. HIV is a serious threat to Africa, but at a high cost, the treatments are unaffordable; this will be the first complete treatment of HIV in Africa. DEI BioPharma is expanding its API manufacturing to similar, expensive, and urgent products, serving the needs of developing countries as the first company in the world to do so. DEI BioPharma plans to launch this new drug within 18 months.
ISSUED BY MANAGING DIRECTOR
ABOUT DEI BIOPHARMA LTD
Leading Africa in Pharmaceuticals Research and Innovation
Dei BioPharma Ltd is a biotech and pharmaceutical research firm duly incorporated in Uganda, specializing in the development and manufacture of innovative medicines and vaccines.
Under the leadership of Uganda scientist Dr. Magoola Matthias, the Founder and Managing Director, Dei BioPharma, is investing in novel research and owns over 100 patents filed with the United States Patent and Trademark Office (USPTO) that cover its technology.
The firm is currently engaged in the development of an iconic Drugs and Vaccines Manufacturing Facility that was commissioned in July 2021 by President Yoweri Museveni and Kenya President William Ruto (then Vice President).
The state-of-the-art facility is situated in Matugga, Wakiso district, near Kampala- Uganda, and sitting on a campus of over 250-acres of land , shall produce high-quality medicines across a wide range of therapeutic areas powered by about 30 manufacturing units.
These include Malaria, HIV-Aids, Cancer, Generics, Beta-lactams, Non beta-lactams, Hormones, Liquids, Nutraceuticals, Parenterals, Heparin, APIs, Insulin glargine, Vaccines, Cephalosporins, Monoclonal antibodies, mRNA based therapeutics.
The manufacturing facility is gearing to produce one billion doses of mRNA vaccines and key biological drugs guided by the most stringent Global GMP, including the US FDA, EU (EMA) and the World Health Organization (WHO) standards.
Dei BioPharma will create more than 40,000 professional jobs, especially for scientists and other professions for the Uganda economy.
